Prescribing Information and Adverse Events Reporting
Prescribing Information and Adverse Events Reporting
ADVATE (octocog alfa)
CEPROTIN® (human protein c)
CINRYZE® ▼ (human c1-esterase inhibitor)
CUVITRU® (human normal immunoglobulin)
ELAPRASE® ▼ (idursulfase)
FEIBA® (factor VIII inhibitor bypassing activity)
FIRAZYR® (icatibant)
HYQVIA® (human normal immunoglobulin)
KIOVIG® (human normal immunoglobulin)
LIVTENCITY® ▼ (maribavir)
OBIZUR® ▼ (susoctocog alfa)
PROTHROMPLEX TOTAL® (human prothrombin complex)
REPLAGAL® (agalsidase alfa)
TAKHZYRO® (lanadelumab)
VEYVONDI® (vonicog alfa)
VPRIV® (velaglucerase alfa)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Takeda UK Ltd. at: AE.GBR-IRL@takeda.com
